多形膠芽腫（GBM）治療の世界市場レポート 2025年

多形膠芽腫（GBM）治療市場は、高齢者人口の増加により成長が見込まれています。65歳以上の高齢者には特有の健康上の配慮が必要であり、高齢のGBM患者に合わせた治療戦略の開発につながります。世界保健機関（WHO）によると、2030年までに世界の6人に1人が60歳以上となり、2050年には21億人の高齢者に達するといいます。この人口動態の変化は、GBM治療市場の成長を促進する重要な要因です。

市場の主要企業は、競争力を維持するため、革新的なウェアラブル機器やポータブル機器の開発に注力しています。これらの進歩は、機能性、利便性、快適性の向上をユーザーに提供することを目的としており、アクセスしやすく効率的なヘルスケアソリューションに対する需要の高まりに対応しています。例えば、2023年には、ジャージー州に本社を置く腫瘍学企業のNovocure社が、新たに膠芽腫（GBM）と診断された患者向けのウェアラブルでポータブルな治療システムであるOptune Gioを発表し、FDAの承認を取得しました。この装置は、がん細胞の分裂を妨げる交互電界である腫瘍治療電界（TTFields）を利用し、患者の生存率を高める可能性があります。重さわずか2.7ポンドのOptune Gioは、患者が日常生活中に装着できるよう、快適性を重視して設計されています。

大手企業は、高度で的を絞った治療ソリューションの需要に応えるため、放射性医薬品治療のような革新的治療を優先しています。放射性医薬品治療は、放射性物質を用いて特定の組織や細胞に標的放射線を照射するもので、がん細胞を破壊するがん治療で一般的に採用されています。例えば、2022年2月、分子放射線治療と分子画像診断製品のプロバイダーである英国のTheragnostics社は、I-123 PARPi（THG-009）療法の開発を発表しました。英国MHRAからイノベーション・パスポートを付与されたこの革新的な治療法は、原発性および再発性の多形膠芽腫（GBM）に対処することを目的としており、第1相臨床試験に進んでいます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界多形膠芽腫（GBM）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の多形膠芽腫（GBM）治療市場：成長率分析
• 世界の多形膠芽腫（GBM）治療市場の実績：規模と成長, 2019-2024
• 世界の多形膠芽腫（GBM）治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界多形膠芽腫（GBM）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の多形膠芽腫（GBM）治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 放射線治療
• 化学療法
• 標的療法
• 腫瘍治療場（TTF）療法
• 免疫療法
• 世界の多形膠芽腫（GBM）治療市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• テモゾロミド
• ベバシズマブ
• ロムスチン
• カルムスチンウェーハ
• その他の薬物クラス
• 世界の多形膠芽腫（GBM）治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の多形膠芽腫（GBM）治療市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 外来手術センター
• 世界の多形膠芽腫（GBM）治療市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍切除
• 生検手順
• 世界の多形膠芽腫（GBM）治療市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療（EBRT）
• 定位放射線治療
• 世界の多形膠芽腫（GBM）治療市場、化学療法の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準化学療法
• 併用化学療法レジメン
• 世界の多形膠芽腫（GBM）治療市場、標的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• EGFR阻害剤
• その他の標的エージェント
• 世界の多形膠芽腫（GBM）治療市場、腫瘍治療野（TTF）療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デバイスベースのTTF治療
• 世界の多形膠芽腫（GBM）治療市場、免疫療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チェックポイント阻害剤
• ワクチンベースの治療法

第7章 地域別・国別分析

• 世界の多形膠芽腫（GBM）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の多形膠芽腫（GBM）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多形膠芽腫（GBM）治療市場：競合情勢
• 多形膠芽腫（GBM）治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Jazz Pharmaceuticals Inc.
• Sumitomo Dainippon Pharma Oncology Inc.
• Varian Medical Systems Inc.
• Amneal Pharmaceuticals Inc.
• Elekta AB
• ANI Pharmaceuticals Inc.
• Accord Healthcare Limited
• The Eckert & Ziegler Group
• Loxo Oncology Inc.
• Karyopharm Therapeutics Inc.
• Celon Laboratories Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 多形膠芽腫（GBM）治療市場2029：新たな機会を提供する国
• 多形膠芽腫（GBM）治療市場2029：新たな機会を提供するセグメント
• 多形膠芽腫（GBM）治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Glioblastoma multiforme (GBM) treatment involves the management and care of patients diagnosed with glioblastoma multiforme, a rapidly growing type of tumor located in the brain or spinal cord. This primary malignant brain tumor has the highest prevalence rate among adults.

The primary treatments for glioblastoma multiforme (GBM) include surgery, radiation therapy, chemotherapy, targeted therapy, tumor-treating field (TTF) therapy, and immunotherapy. Surgery is a medical discipline that concentrates on employing manual and instrumental methods to treat wounds, illnesses, and other conditions. The types of drugs involved in GBM treatment include temozolomide, bevacizumab, lomustine, carmustine wafers, and others. These medications are administered through oral, parenteral, and various other routes of administration and are used by hospitals, clinics, and ambulatory surgical centers.

The glioblastoma multiforme (GBM) treatment market research report is one of a series of new reports from The Business Research Company that provides glioblastoma multiforme (GBM) treatment market statistics, including glioblastoma multiforme (GBM) treatment industry global market size, regional shares, competitors with glioblastoma multiforme (GBM) treatment market share, detailed glioblastoma multiforme (GBM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the glioblastoma multiforme (GBM) treatment industry. This glioblastoma multiforme (GBM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The glioblastoma multiforme (GBM) treatment market size has grown rapidly in recent years. It will grow from $2.48 billion in 2024 to $2.74 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increased incidence and prevalence, advancements in diagnostic techniques, clinical trials and research funding, collaborations and partnerships, improved understanding of tumor biology.

The glioblastoma multiforme (GBM) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.1 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to emergence of immunotherapies, precision medicine advancements, expanded knowledge of genetic markers, patient advocacy and awareness, government support for rare diseases. Major trends in the forecast period include exploration of combination therapies, integration of artificial intelligence in diagnosis and treatment planning, rise in adoption of immunotherapeutic approaches, advance medical tools and equipment.

The rising prevalence of brain disorders is anticipated to drive the growth of the glioblastoma multiforme (GBM) treatment market in the coming years. Brain disorders encompass the abnormal functioning of the brain, as well as the nerves throughout the body and the spinal cord. The growing incidence of brain disorders, including glioblastoma multiforme (GBM), is attributed to various factors such as an aging population, weakened immune systems, overdiagnosis, exposure to ionizing radiation, air pollution, and others. These factors contribute to the increasing demand for treatments aimed at improving well-being. For example, a report by the American Cancer Society, a US-based voluntary health organization focused on eliminating cancer, indicated that in 2022, approximately 25,050 cases of malignant tumors of the brain or spinal cord were diagnosed in the US. Therefore, the rising prevalence of brain disorders is a significant driver of growth in the glioblastoma multiforme (GBM) treatment market.

The glioblastoma multiforme (GBM) treatment market is expected to grow due to the rising geriatric population. The elderly, aged 65 and older, present specific health considerations, leading to the development of treatment strategies tailored for older patients with GBM. According to the World Health Organization, by 2030, 1 in 6 individuals globally will be 60 or older, reaching 2.1 billion elderly people by 2050. This demographic shift is a key factor propelling the growth of the GBM treatment market.

Leading companies in the market are concentrating on developing innovative wearable and portable devices to maintain their competitive edge. These advancements aim to provide users with improved functionality, convenience, and comfort, addressing the increasing demand for accessible and efficient healthcare solutions. For example, in 2023, Novocure, an oncology company based in Jersey, introduced Optune Gio, a wearable and portable treatment system for patients with newly diagnosed glioblastoma (GBM), which has received FDA approval. This device utilizes Tumor Treating Fields (TTFields), which are alternating electric fields that interfere with cancer cell division, potentially enhancing patient survival. Weighing just 2.7 pounds, Optune Gio is designed for comfort, allowing patients to wear it during their daily activities.

Major companies are prioritizing innovative treatments such as radiopharmaceutical therapy to meet the demand for advanced and targeted therapeutic solutions. Radiopharmaceutical therapy involves using radioactive substances to deliver targeted radiation to specific tissues or cells, commonly employed in cancer treatment to destroy cancer cells. For instance, in February 2022, Theragnostics, a UK-based provider of molecular radiotherapy and molecular imaging diagnostic products, announced the development of I-123 PARPi (THG-009) therapy. This innovative therapy, granted an Innovation Passport by the UK MHRA, aims to address primary and recurrent Glioblastoma Multiforme (GBM) and is advancing to a Phase 1 clinical trial.

In April 2022, Elekta, a Sweden-based company providing radiation therapy, radiosurgery, related equipment, and clinical management for cancer treatment, signed a global commercial collaboration agreement with GE Healthcare, a US-based manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals. This collaboration enables them to offer comprehensive solutions across imaging and treatment for cancer patients requiring radiation therapy. The partnership facilitates the joint promotion of solutions tailored to the needs of each cancer center.

Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healthcare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.

North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glioblastoma multiforme (gbm) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glioblastoma multiforme (GBM) treatment market includes revenues earned by entities by performing neurological exams, imaging tests, surgical operations, radiotherapy, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glioblastoma Multiforme (GBM) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glioblastoma multiforme (gbm) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glioblastoma multiforme (gbm) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glioblastoma multiforme (gbm) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Tumor Treating Field (TTF) Therapy; Immunotherapy
• 2) By Drug Class: Temozolomide; Bevacizumab; Lomustine; Carmustine Wafers; Other Drug Classes
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 4) By End-Use: Hospitals; Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Surgery: Tumor Resection; Biopsy Procedures
• 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Radiation Therapy
• 3) By Chemotherapy: Standard Chemotherapy; Combination Chemotherapy Regimens
• 4) By Targeted Therapy: EGFR Inhibitors; Other Targeted Agents
• 5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
• 6) By Immunotherapy: Checkpoint Inhibitors; Vaccine-Based Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glioblastoma Multiforme (GBM) Treatment Market Characteristics

3. Glioblastoma Multiforme (GBM) Treatment Market Trends And Strategies

4. Glioblastoma Multiforme (GBM) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Glioblastoma Multiforme (GBM) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Glioblastoma Multiforme (GBM) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Glioblastoma Multiforme (GBM) Treatment Market Growth Rate Analysis
• 5.4. Global Glioblastoma Multiforme (GBM) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Glioblastoma Multiforme (GBM) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Glioblastoma Multiforme (GBM) Treatment Total Addressable Market (TAM)

6. Glioblastoma Multiforme (GBM) Treatment Market Segmentation

• 6.1. Global Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Tumor Treating Field (TTF) Therapy
• Immunotherapy
• 6.2. Global Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Temozolomide
• Bevacizumab
• Lomustine
• Carmustine Wafers
• Other Drug Classes
• 6.3. Global Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.4. Global Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• 6.5. Global Glioblastoma Multiforme (GBM) Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Resection
• Biopsy Procedures
• 6.6. Global Glioblastoma Multiforme (GBM) Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Stereotactic Radiation Therapy
• 6.7. Global Glioblastoma Multiforme (GBM) Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Chemotherapy
• Combination Chemotherapy Regimens
• 6.8. Global Glioblastoma Multiforme (GBM) Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• EGFR Inhibitors
• Other Targeted Agents
• 6.9. Global Glioblastoma Multiforme (GBM) Treatment Market, Sub-Segmentation Of Tumor Treating Field (TTF) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Device-Based TTF Treatment
• 6.10. Global Glioblastoma Multiforme (GBM) Treatment Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Vaccine-Based Therapies

7. Glioblastoma Multiforme (GBM) Treatment Market Regional And Country Analysis

• 7.1. Global Glioblastoma Multiforme (GBM) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Glioblastoma Multiforme (GBM) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market

• 8.1. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glioblastoma Multiforme (GBM) Treatment Market

• 9.1. China Glioblastoma Multiforme (GBM) Treatment Market Overview
• 9.2. China Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glioblastoma Multiforme (GBM) Treatment Market

• 10.1. India Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glioblastoma Multiforme (GBM) Treatment Market

• 11.1. Japan Glioblastoma Multiforme (GBM) Treatment Market Overview
• 11.2. Japan Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glioblastoma Multiforme (GBM) Treatment Market

• 12.1. Australia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glioblastoma Multiforme (GBM) Treatment Market

• 13.1. Indonesia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glioblastoma Multiforme (GBM) Treatment Market

• 14.1. South Korea Glioblastoma Multiforme (GBM) Treatment Market Overview
• 14.2. South Korea Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glioblastoma Multiforme (GBM) Treatment Market

• 15.1. Western Europe Glioblastoma Multiforme (GBM) Treatment Market Overview
• 15.2. Western Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glioblastoma Multiforme (GBM) Treatment Market

• 16.1. UK Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glioblastoma Multiforme (GBM) Treatment Market

• 17.1. Germany Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glioblastoma Multiforme (GBM) Treatment Market

• 18.1. France Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glioblastoma Multiforme (GBM) Treatment Market

• 19.1. Italy Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glioblastoma Multiforme (GBM) Treatment Market

• 20.1. Spain Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market

• 21.1. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market Overview
• 21.2. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glioblastoma Multiforme (GBM) Treatment Market

• 22.1. Russia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glioblastoma Multiforme (GBM) Treatment Market

• 23.1. North America Glioblastoma Multiforme (GBM) Treatment Market Overview
• 23.2. North America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glioblastoma Multiforme (GBM) Treatment Market

• 24.1. USA Glioblastoma Multiforme (GBM) Treatment Market Overview
• 24.2. USA Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glioblastoma Multiforme (GBM) Treatment Market

• 25.1. Canada Glioblastoma Multiforme (GBM) Treatment Market Overview
• 25.2. Canada Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glioblastoma Multiforme (GBM) Treatment Market

• 26.1. South America Glioblastoma Multiforme (GBM) Treatment Market Overview
• 26.2. South America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glioblastoma Multiforme (GBM) Treatment Market

• 27.1. Brazil Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glioblastoma Multiforme (GBM) Treatment Market

• 28.1. Middle East Glioblastoma Multiforme (GBM) Treatment Market Overview
• 28.2. Middle East Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glioblastoma Multiforme (GBM) Treatment Market

• 29.1. Africa Glioblastoma Multiforme (GBM) Treatment Market Overview
• 29.2. Africa Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Glioblastoma Multiforme (GBM) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glioblastoma Multiforme (GBM) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Glioblastoma Multiforme (GBM) Treatment Market Competitive Landscape
• 30.2. Glioblastoma Multiforme (GBM) Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Glioblastoma Multiforme (GBM) Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Amgen Inc.
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Sun Pharmaceutical Industries Limited
• 31.5. Jazz Pharmaceuticals Inc.
• 31.6. Sumitomo Dainippon Pharma Oncology Inc.
• 31.7. Varian Medical Systems Inc.
• 31.8. Amneal Pharmaceuticals Inc.
• 31.9. Elekta AB
• 31.10. ANI Pharmaceuticals Inc.
• 31.11. Accord Healthcare Limited
• 31.12. The Eckert & Ziegler Group
• 31.13. Loxo Oncology Inc.
• 31.14. Karyopharm Therapeutics Inc.
• 31.15. Celon Laboratories Pvt. Ltd.

32. Global Glioblastoma Multiforme (GBM) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glioblastoma Multiforme (GBM) Treatment Market

34. Recent Developments In The Glioblastoma Multiforme (GBM) Treatment Market

35. Glioblastoma Multiforme (GBM) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Glioblastoma Multiforme (GBM) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Glioblastoma Multiforme (GBM) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Glioblastoma Multiforme (GBM) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer